Dasatinib-Induced Bilateral Chylothorax: A Case Report
- PMID: 39360083
- PMCID: PMC11446622
- DOI: 10.7759/cureus.68479
Dasatinib-Induced Bilateral Chylothorax: A Case Report
Abstract
Dasatinib, a BCR-ABL tyrosine kinase inhibitor, is used in the management of Philadelphia-positive chronic myeloid leukemia (CML). Several adverse complications of this targeted immunotherapy have been reported. This case report focuses on a 79-year-old female who presented with acute dyspnea and generalized chest pressure while undergoing management with this specific tyrosine kinase inhibitor. Bilateral chylothorax was diagnosed with the aid of imaging, laboratory studies, and diagnostic thoracentesis. No other risk factors, including trauma, lung malignancies, or congenital anomalies, were detected in this patient. Since no other etiologies for the development of chylothorax were identified, it was concluded that dasatinib therapy was the inciting factor. Dasatinib was discontinued and bosutinib was initiated. A low-fat diet was prescribed, which the patient was amenable to. Six months later, the patient remained stable with no recurrence of chylothorax. The mechanism of dasatinib-induced chylothorax is currently under investigation. The purpose of this report is to raise awareness about dasatinib-induced chylothorax, aid in identifying predisposing risk factors, and enhance understanding of the proper management of this rare complication.
Keywords: #dasatinib; acute dyspnea; bcr-abl positive; bilateral chylothorax; bilateral pleural effusion; chronic myeloid leukemia (cml); exudative pleural effusion; philadelphia chromosome positive.
Copyright © 2024, McGonegal et al.
Conflict of interest statement
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures




Similar articles
-
Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.Transl Cancer Res. 2023 Jan 30;12(1):194-200. doi: 10.21037/tcr-22-1983. Epub 2023 Jan 6. Transl Cancer Res. 2023. PMID: 36760377 Free PMC article.
-
Dasatinib-induced chylothorax: report of a case and review of the literature.Invest New Drugs. 2020 Oct;38(5):1627-1632. doi: 10.1007/s10637-020-00932-3. Epub 2020 Apr 4. Invest New Drugs. 2020. PMID: 32248338 Review.
-
Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.Am J Case Rep. 2022 Nov 29;23:e938319. doi: 10.12659/AJCR.938319. Am J Case Rep. 2022. PMID: 36444127 Free PMC article.
-
Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia.Respir Med Case Rep. 2022 May 5;37:101662. doi: 10.1016/j.rmcr.2022.101662. eCollection 2022. Respir Med Case Rep. 2022. PMID: 35585905 Free PMC article.
-
Low-dose dasatinib-induced chylothorax, pulmonary hypertension, and pericardial effusion in a patient with chronic myeloid leukemia: A case report and literature review.Medicine (Baltimore). 2025 Jan 17;104(3):e41328. doi: 10.1097/MD.0000000000041328. Medicine (Baltimore). 2025. PMID: 39833041 Free PMC article. Review.
References
-
- Chronic myeloid leukemia (CML) [ Jul; 2024 ]. 2024. https://www.cancer.org/cancer/types/chronic-myeloid-leukemia.html https://www.cancer.org/cancer/types/chronic-myeloid-leukemia.html
-
- Chronic myeloid leukemia. [ Jul; 2024 ];Melo JV, Hughes TP, Apperley JF. Hematology Am Soc Hematol Educ Program. 2003 5:132–152. - PubMed
-
- Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. [ Jul; 2024 ];Seong D, Kantarjian HM, Albitar M, et al. Ann Oncol. 1999 10:955–959. - PubMed
-
- Dasatinib. [ Jul; 2024 ]. 2024. https://pubchem.ncbi.nlm.nih.gov/compound/Dasatinib https://pubchem.ncbi.nlm.nih.gov/compound/Dasatinib
-
- Sprycel. [ Jul; 2024 ]. 2024. https://www.sprycel.com/ https://www.sprycel.com/
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous